History of major cardiovascular surgery

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared with simvastatin alone in the overall ACCORD-Lipid cohort of patients with Type 2 diabetes (2.2

Effect: null; HR 0.92; CI: 95% CI 0.79-1.08

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate

In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/dl and HDL-C <=34 mg/dl, representing 17% of the cohort), fenofibrate plus simvastatin was associate

Effect: improvement; 31% lower event rate